Literature DB >> 12772051

High interobserver variability in endosonographic staging of upper gastrointestinal cancers.

A Meining1, T Rösch, A Wolf, R Lorenz, H D Allescher, W Kauer, H J Dittler.   

Abstract

Mostly based on results of experienced examiners, endoscopic ultrasound (EUS) has been reported to be highly accurate for locoregional staging of upper gastrointestinal cancers. However, data on interobserver variability among EUS examiners, depending on their experience levels, is sparse. A study was therefore conducted to analyse well-documented videotapes of EUS examinations of 108 patients with resected cancers of the esophagus (n = 55) or stomach (n = 53) in a strictly blinded fashion by 5 examiners, all of whom were experienced in EUS (more than 300 examinations: n = 3, more than 100 examinations: n = 2). Besides the individual accuracy rates in cancer staging, a kappa-statistic was calculated to check for interobserver variability. Under the conditions described, the staging accuracy of all investigators was lower than that usually achieved under clinical routine conditions. The mean T staging accuracy was 41.1 % +/- 9.4 and 46.9 % +/- 5.4 in gastric and esophageal cancers, respectively. For N-staging the respective values were 47.9 % +/- 5.1 (stomach) and 67.7 % +/- 5.4 (oesophagus). Kappa-values were above 0.4 only in the staging of non-invasive esophagogastric tumours of the N0 and T1-category, corresponding to a fairly good agreement among the five investigators. Differences depending on experience levels could not be consistently found. Hence, it can be concluded that endosonographic cancer staging performed in a blinded manner results in a low accuracy and high interobserver variability even among experienced examiners.

Entities:  

Mesh:

Year:  2003        PMID: 12772051     DOI: 10.1055/s-2003-39422

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  9 in total

Review 1.  [R1 resection in the surgery of upper gastrointestinal tumors: relevance and therapeutic consequences].

Authors:  F Lordick; K Ott; A Novotny; C Schuhmacher; J R Siewert
Journal:  Chirurg       Date:  2007-09       Impact factor: 0.955

2.  Plectin-1 as a novel biomarker for pancreatic cancer.

Authors:  Dirk Bausch; Stephanie Thomas; Mari Mino-Kenudson; Castillo Carlos Fernández-del; Todd W Bauer; Mark Williams; Andrew L Warshaw; Sarah P Thayer; Kimberly A Kelly
Journal:  Clin Cancer Res       Date:  2010-11-23       Impact factor: 12.531

3.  Does endoscopic ultrasound staging already allow individual treatment regimens in gastric cancer.

Authors:  Stojan Potrc; Marjan Skalicky; Arpad Ivanecz
Journal:  Wien Klin Wochenschr       Date:  2006       Impact factor: 1.704

4.  How radical should surgery be for early esophageal cancer?

Authors:  Dean Bogoevski; Maximilian Bockhorn; Alexandra Koenig; Matthias Reeh; Katharina von Loga; Guido Sauter; Thomas Rösch; Jakob R Izbicki
Journal:  World J Surg       Date:  2011-06       Impact factor: 3.352

5.  Endoscopic Ultrasound Stagingof Esophageal Cancer.

Authors:  Shyam Thakkar; Vivek Kaul
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-01

Review 6.  Clinical approach to the patient with a solid pancreatic mass.

Authors:  Reinhold Függer; Odo Gangl; Uwe Fröschl
Journal:  Wien Med Wochenschr       Date:  2014-02-28

Review 7.  Endoscopic ultrasonography for surveillance of individuals at high risk for pancreatic cancer.

Authors:  Gabriele Lami; Maria Rosa Biagini; Andrea Galli
Journal:  World J Gastrointest Endosc       Date:  2014-07-16

Review 8.  Pancreatic cancer--EUS and early diagnosis.

Authors:  Lars Helmstaedter; Juergen Ferdinand Riemann
Journal:  Langenbecks Arch Surg       Date:  2008-02-05       Impact factor: 3.445

9.  Endoscopic ultrasound for the evaluation of Nissen fundoplication integrity: a blinded comparison with conventional testing.

Authors:  E Y Chang; R C Minjarez; C Y Kim; A K Seltman; D V Gopal; B Diggs; R Davila; J G Hunter; B A Jobe
Journal:  Surg Endosc       Date:  2007-03-08       Impact factor: 4.584

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.